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The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II
trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups.
Patients received pemetrexed 500mgm
 2 and carboplatin AUC 5mgml
 1min
 1 intravenously every 21 days with standard vitamin
supplementation. Elderly patients were defined as those X70 years old. A total of 178 patients with an ECOG performance status of
p2 were included. Median age was 65 years (range 38–79), with 48 patients X70 years (27%). Grade 3–4 haematological toxicity
was slightly worse in X70 vs o70-year-old patients, with neutropenia observed in 25.0 vs 13.8% (P¼0.11), anaemia in 20.8 vs 6.9%
(P¼0.01) and thrombocytopenia in 14.6 vs 8.5% (P¼0.26). Non-haematological toxicity was mild and similar in the two groups. No
significant difference was observed in terms of overall disease control (60.4 vs 66.9%, P¼0.47), time to progression (7.2 vs 7.5
months, P¼0.42) and survival (10.7 vs 13.9 months, P¼0.12). Apart from slightly worse haematological toxicity, there was no
significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly
patients with MPM.
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The incidence of malignant pleural mesothelioma (MPM) is
increasing in most of the world, and is expected to rise in the
next 10–15 years in Europe (Robinson and Lake, 2005). Owing to
the long latent period following asbestos exposure, MPM is often
diagnosed late in life. A high rate of diagnosis in elderly patients is
reported by several mesothelioma registers and epidemiological
studies (Price and Ware, 2004; Marinaccio et al, 2005). The median
age of disease onset in the United States has been recently reported
to be 74 years, according to the Surveillance, Epidemiology, and End
Results database (SEER Database, 2007). A similar trend has been
reported in western European countries (Hodgson et al,2 0 0 5 ) .
A minority of patients with MPM is eligible for surgical
treatment (Sugarbaker et al, 1999); most are candidates for
chemotherapy during the course of their disease. Recently, the
novel multitargeted antifolate pemetrexed was shown to have
activity in MPM as a single agent and in combination with
platinum compounds (Hughes et al, 2002; Scagliotti et al, 2003;
Vogelzang et al, 2003). A large phase III trial testing pemetrexed
and cisplatin vs cisplatin alone in 448 chemo-naive patients with
MPM showed a significant advantage in survival, time to
progression (TTP) and response rate (RR) with the combined
regimen (Vogelzang et al, 2003). Following the results of this trial,
the combination of cisplatin and pemetrexed has become
established as the standard of care in systemic therapy for MPM
(Hazarika et al, 2005). However, the typical non-haematological
toxicity profile of cisplatin is questionable in the context of a
palliative treatment; furthermore, many MPM patients, and
especially elderly patients, are unfit to receive cisplatin-based
chemotherapy (Zucali and Giaccone, 2006). Therefore, schedules
with carboplatin have been explored in an attempt to reduce
toxicity, while maintaining the same survival benefit (Hughes et al,
2002; Favaretto et al, 2003; Ceresoli et al, 2006; Castagneto et al,
2008). Recently, we published the results of the combination of
pemetrexed and carboplatin administered as first-line treatment in
102 patients (Ceresoli et al, 2006). In this trial, time to disease
progression and overall survival (OS) were similar to the results
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sachieved with the standard regimen of pemetrexed and cisplatin,
suggesting that the carboplatin combination could be an
alternative option for these patients. These results have been
confirmed independently in another trial using the same treatment
schedule in 76 chemo-naive patients (Castagneto et al, 2008).
Despite the increase in the incidence of MPM with age, elderly
patients are under-represented in clinical trials. The median age of
the patients enrolled in the cisplatin/pemetrexed phase III trial was
61 years (Vogelzang et al, 2003), and the percentage of patients
aged X70 years was about 19% (Vogelzang and Symanowski,
personal communication). Median patient age was 58 years in
another large phase III trial of the combination of cisplatin and
raltitrexed vs cisplatin alone (Van Meerbeeck et al, 2005).
Prospective as well as retrospective data regarding the
tolerability and efficacy of anticancer treatments for elderly
patients affected by MPM are lacking. The aim of this study was
to perform a pooled retrospective analysis using individual patient
data from two phase II trials that included patients treated with the
same treatment schedule of carboplatin and pemetrexed, compar-
ing the efficacy, toxicity and survival outcomes of this combination
in elderly vs younger patients. Elderly patients were defined as
those X70 years old.
PATIENTS AND METHODS
Patient population
The two trials that comprised this pooled analysis were prospective
phase II studies conducted between November 2002 and July 2005,
which enrolled chemo-naive patients with histologically proven
MPM who were not candidates for surgery. Eligibility criteria were
nearly identical in the two studies (Table 1), and included an
Eastern Cooperative Oncology Group (ECOG) performance status
p2 and an estimated life expectancy of X12 weeks. The presence
of unidimensionally and/or bidimensionally measurable disease
was mandatory. Adequate bone marrow, renal and hepatic
function, as assessed by laboratory tests, was required. Prior
systemic or intracavitary chemotherapy, documented brain
metastases, serious co-morbidities or other malignancies were
not allowed. Patients with a measurable recurrence after surgery
were considered eligible. Both were age-unspecified trials; the
patients had to be aged X18 years. Written informed consent was
obtained from each patient. Both studies were conducted after
approval by the appropriate ethical review boards.
Trials and patient selection
The patients included in the two trials represented about 60% of
the total population of patients with a diagnosis of chemo-naive
MPM, referred to the participating centres during the study
periods (Figure 1). Patients not enrolled in the two studies were
excluded for several reasons, mainly because they were candidates
for multimodality programs including surgery, or because they
were treated with supportive care only (due to poor performance
status) or with other chemotherapy regimens, such as single-agent
pemetrexed, cisplatin and pemetrexed or cisplatin and gemcita-
bine. Overall, nearly half of the patients over 70 years were
included in the two trials with pemetrexed/carboplatin. Of the
elderly patients not treated with carboplatin and pemetrexed, most
received single-agent pemetrexed (17 patients), intrapleural
treatments (20 cases) or supportive care only (8 patients).
Study design
A retrospective analysis was conducted using individual patient
data for all of the patients included in the two studies. Follow-up
was updated to March 2008. Both studies consisted of a phase II
trial of the combination of pemetrexed and carboplatin as first-line
treatment in unresectable MPM (Ceresoli et al, 2006; Castagneto
et al, 2008). In study A, patients from eight Italian institutions were
enrolled prospectively; study B included patients from three other
national centres. According to the original protocols, the primary
end point of both studies was tumour RR. Secondary end points
included toxicity, time to progressive disease (TTP) and OS. In the
pooled analysis, the focus of which was on the effect of age, several
different end points were explored. In particular, baseline
differences between elderly (X70 years) and younger (o70 years)
patients were assessed. Moreover, the efficacy, toxicity and survival
outcomes of this combination in elderly vs younger patients were
compared.
Patient assessment
Baseline assessment for all patients included a complete medical
history and physical examination, full blood count and blood
chemistry. A CT scan of the chest and abdomen was performed.
Patients were staged according to the TNM staging system
proposed by the International Mesothelioma Interest Group
(Rusch, 1995). Best tumour response was evaluated according to
different criteria in the two trials: in trial A hybrid uni/
bi-dimensional criteria were used (Vogelzang et al, 2003); in trial
B the response was assessed according to modified RECIST criteria
(Byrne and Nowak, 2004). No confirmatory scans were performed
on patients exhibiting partial response (PR) or stable disease (SD)
in either study. Overall disease control was defined as the
percentage of patients achieving an objective response or SD.
Treatment toxicity was evaluated according to the NCI Common
Toxicity Criteria (CTC) version 2.0 grading system (National
Cancer Institute, 1999). After completion of the study treatment,
patients were evaluated with chest and abdominal CT scans every 2
months until disease progression. Patients were also followed up
for survival until death or last contact if still alive. No second-line
therapy was planned in either trial. Time to progression was
defined as time from study entry (first day of study treatment)
Table 1 Main trial characteristics
Trial A Trial B
Ceresoli et al
(2006)
Castagneto et al
(2008)
Accrual period November 2002–
March 2005
July 2003–July 2005
Total accrual, no. of patients 102 76
No. of patients X70 years 32 16
Age restrictions X18 years X18 years
289 chemo-naive MPM patients
111 patients NOT INCLUDED in trials
with pemetrexed/carboplatin
178 patients INCLUDED in trials
with pemetrexed/carboplatin 
5070 years 4870 years 61< 70 years 130 < 70 years
Figure 1 Therapeutic management of the total population of chemo-
naive patients with malignant pleural mesothelioma (MPM) referred to the
participating centres during the study period. Patients aged X70 years
represented 34% (98 of 298) of new cases of MPM.
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suntil time of disease progression (as shown by radiological or
clinical examination) or death from any cause. Patients without
any evidence of progressive disease were censored at the date of
the last follow-up for the purpose of this analysis. Overall survival
was calculated as the time from study entry until death from any
cause; patients who were alive on the date of last follow-up were
censored on that date.
Treatment
The treatment schedule was the same in the two trials. Pemetrexed
was administered intravenously at a dose of 500mgm
 2 over
10min, followed by carboplatin, administered by a 30-min
intravenous infusion at an AUC of 5mgml
 1min
 1. Both drugs
were given on day 1, every 21 days. All patients received standard
vitamin supplementation with folic acid and vitamin B12 plus
steroid prophylaxis. Standard antiemetic therapy with intravenous
5-HT3 antagonists was given before chemotherapy.
Statistical analysis
Differences in baseline characteristics, rates of response and
adverse events in the two groups (X70 vs o70-year patients) were
assessed with Fisher’s exact test (Agresti, 1992). Ninety-five per
cent confidence intervals for RRs were calculated (Leemis and
Trivedi, 1996). Actuarial survival curves were generated using the
method of Kaplan and Meier (Kaplan and Meier, 1958). Time to
progression and OS in the X70 and o70-year groups were
compared through the Mantel–Cox version of the log-rank test
(Cox, 1972). Multivariate analysis using a proportional hazard
model was also used to estimate the effect of age on survival after
controlling for related covariates. All probability values were two-
sided. Statistical analysis was performed using the software
package SAS, version 9.1.3.
RESULTS
Patient characteristics
A total of 178 patients were included in the analysis. The median
age of the study population was 65 years (range 38–79). Forty-
eight patients (27% of the whole study population) were X70 years
old; 11 patients (6%) were X75 years old. Patient characteristics in
terms of gender, ECOG performance status, histology and stage
were similar in the two age groups (Table 2). Most patients had a
performance status p1 and epithelial histological subtype.
Efficacy
All 178 patients were assessable for best tumour response, which
was established according to an intent-to-treat analysis. No patient
experienced a complete response in the X70 years group, whereas
a PR was achieved in seven patients, for an objective RR of 14.6%
(95% CI:6.1–27.8%). In the o70 years group, five patients had a
complete response and 26 a PR; the RR was 23.8% (95% CI:
16.8–32.1%). The RRs did not differ significantly between the two
age groups (P¼0.15). A similar proportion of patients had
SD in the two cohorts: 22 in the X70 years group (45.8, 95%
CI:31.4–60.8%) and 56 in the o70 years group (43.1, 95%
CI:34.4–52.0%) (P¼0.86). Overall disease control was also not
significantly different: 60.4% of the elderly patients (95% CI:45.3–
74.2%) achieved disease control vs 66.9% (95% CI:!58.1–74.9%) of
their younger counterparts (P¼0.47).
With a median follow-up of 37.1 months, 16 patients were still
alive, 8 of whom were without any evidence of disease progression.
The median TTP and OS for the whole study population were 7.4
and 13.8 months, respectively. Time to progression and OS did not
differ significantly between the two age cohorts even after
adjusting for different prognostic factors, such as gender, PS,
stage and histology. Figure 2 shows the actuarial TTP curves for
the two age groups; the median TTP for patients X70 and o70
years were 7.2 and 7.5 months, respectively (P¼0.42). Younger
patients had longer median OS (13.9 months) than those aged X70
years (10.7 months), but the difference was not statistically
significant (P¼0.12) (Figure 3). The 6-months and 1-year
estimates of survival were 69 and 48% for patients X70 years,
and 76 and 55% for those aged o70 years.
Toxicity
Patients aged X70 and o70 years received a median of six cycles
of treatment; the ranges were 1–12 cycles for elderly and 1–13
cycles for younger patients, respectively. Forty elderly patients
(83%) completed at least four cycles, as compared to 109 (84%) of
younger patients. Haematological toxicity by age group is
summarized in Table 3. Grade 3–4 neutropenia was slightly worse
in elderly patients (25.0 vs 13.8%; P¼0.11); however, febrile
neutropenia was observed less frequently in this age group (2.1 vs
3.8%). Severe anaemia was significantly more frequent in older
patients (20.8 vs 6.9%; P¼0.01), occurring mainly as cumulative
toxicity. Grade 3–4 thrombocytopenia occurred in 14.6% of the
elderly vs 8.5% of the younger patients (P¼0.26). When all toxicity
grades were considered (data not shown), neutropenia and
anaemia rates remained higher in the elderly patients (P¼0.03
and P¼0.0009, respectively), while thrombocytopenia did not
differ significantly between the two groups (P¼0.73). Non-
haematological toxicity was mild and similar in the two groups
(Table 4). Nausea and vomiting, fatigue, conjunctivitis and
diarrhoea were the most commonly reported adverse effects of
treatment (Table 4). One case of acute rhabdomyolysis with slow
resolution was observed in a 68-year-old male patient (Ceresoli
et al, 2006; Ceribelli et al, 2006). No treatment-related deaths were
observed in either of the age groups.
DISCUSSION
Elderly patients account for the majority of all new cancer cases.
According to an estimate, 61% of new cancer diagnoses and 70% of
Table 2 Baseline patient characteristics by age group
Patients X70 years
(N¼48) (%)
Patients o70 years
(N¼130) (%) P
Gender
Male 33 (69) 98 (75) 0.37
Female 15 (31) 32 (25)
ECOG performance status
0 16 (33) 52 (40) 0.43
1 28 (58) 69 (53)
2 4 (8) 9 (7)
Histology
Epithelial 36 (75) 101 (78) 0.70*
Mixed 4 (8) 17 (13)
Sarcomatoid 5 (10) 5 (4)
Unclassified 3 (6) 7 (5)
IMIG stage
Stage I 2 (4) 5 (4) 0.34
Stage II 7 (15) 10 (8)
Stage III 16 (33) 45 (34)
Stage IV/relapse
after EPP
23 (48) 70 (54)
*Epithelial vs non-epithelial patients.
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sall cancer deaths occur in people aged 65 years or older (Hutchins
et al, 1999). In the US and in Europe, the number of cancer cases in
older people is expected to increase, as they constitute the most
rapidly growing section of the population (Yancik and Ries, 2000).
However, there is substantial under-representation of these
populations in clinical trials, particularly as regards patients aged
X70 years (Hutchins et al, 1999; Lewis et al, 2003; Talarico et al,
2004; Kumar et al, 2007). This leads to uncertainty about the
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Figure 2 Kaplan–Meier curve of time to disease progression for younger (solid line) and elderly (dotted line) patients (P¼0.42).
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Figure 3 Kaplan–Meier curve of overall survival time for younger (solid line) and elderly (dotted line) patients (P¼0.12).
Table 3 Grade 3–4 haematological toxicity by patient
Patients X70 years (N¼48) Patients o70 years (N¼130)
G3 (No.) G4 (No.) G3–4 (%) G3 (No.) G4 (No.) G3–4 (%) P
Neutropenia 5 7 25.0 13 5 13.8 0.11
Anaemia 9 1 20.8 7 2 6.9 0.01
Thrombocytopenia 6 1 14.6 8 3 8.5 0.26
Febrile neutropenia 1 2.1 5 3.8
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sapplicability of the results of studies to elderly patients in terms of
both the efficacy and toxicity of treatments. In MPM, older age has
been generally considered a negative prognostic factor (Herndon
et al, 1998; Gatta et al, 2006). Apart from age-related biological
differences, this may also have been influenced by a nihilistic
attitude to treatment of this disease (Treasure and Sedrakyan,
2004). As a result, specific trials for elderly patients affected by
MPM are completely lacking, and few data are available to the
clinician to assist in making rational treatment decisions.
Our retrospective analysis showed that patients aged X70 years
can derive as much benefit from chemotherapy with pemetrexed
plus carboplatin as younger patients, with an acceptable burden of
toxicity. Pemetrexed and carboplatin are characterized by a
favourable toxicity profile in older patients (Weiss et al, 2006;
Lichtman et al, 2007), although changes in renal function with age
must be taken into account before their administration. In MPM,
the combination is a valuable alternative to the standard regimen
of pemetrexed and cisplatin, with similar survival benefit (Hughes
et al, 2002; Ceresoli et al, 2006; Castagneto et al, 2008). In a recent
report on more than 1700 chemo-naive MPM patients treated
within the International Expanded Access Program, a nonrando-
mized open-label safety study of pemetrexed as a single agent or in
combination with platinum derivatives, the combination of
pemetrexed with either carboplatin or cisplatin resulted in similar
efficacy and tolerability (Santoro et al, 2007).
In our series, the baseline patient and disease characteristics were
similar between the two age groups; most patients had good
p e r f o r m a n c es t a t u s ,w h i l ed a t ao nc o - m o r b i d i t yw e r en o ta v a i l a b l e ,
raising the possibility of a selection bias to include only fit elderly
patients (Extermann and Hurria, 2007). Notably, only 11 patients were
X75 years; therefore, the results of our study should be regarded with
caution with respect to the ‘oldest of the old’, because no consistent
data are available on the risk/benefit ratio of pemetrexed and
carboplatin chemotherapy in this small subset of patients.
The radiological regression and overall disease control rates did
not differ significantly between patients X70 and o70 years,
although different response criteria were used in the two trials and
response classification was not reviewed centrally. However, in
view of the difficulties in assessing radiological response to
therapy, the survival outcomes seem the best treatment end points
in MPM (Francart et al, 2006; Ceresoli et al, 2007a). The median
TTP was similar in the two age groups (7.2 and 7.5 months for
patients X70 and o70 years, respectively), with curves nearly
overlapping (Figure 2). Younger patients lived longer than elderly
(13.9 vs 10.7 months), but the difference was not statistically
significant. No second-line therapy was planned in the two trials,
and this may have influenced OS data. However, the survival
benefit of second-line therapy in MPM is not proven (Ceresoli
et al, 2007b).
Therapy with carboplatin and pemetrexed was well tolerated in
both age groups (Tables 3 and 4), with similar dose delivery. Non-
haematological toxicity was negligible and did not differ sig-
nificantly between groups. The haematological toxicity was slightly
worse in the elderly population, with a higher rate of grade 3–4
neutropenia and anaemia (Table 3). However febrile neutropenia,
which is commonly used as surrogate for unacceptable toxicity,
was uncommon and was not increased in the elderly group.
Moreover, no toxic death was reported.
In conclusion, our data suggest that chemotherapy with
pemetrexed and carboplatin is effective and safe in elderly patients
with good performance status affected by MPM. Extra caution is
required for patients aged X75 years due to the lack of data in this
small age subgroup. Prospective evaluation of this regimen in
specific trials on elderly MPM patients is warranted.
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